To avoid unnecessary binding on peripheral effector cells, which may also reduce PD-1-mediated tumor targeting effect, we first tested whether mIL12mut2 with lower affinity was preferable for fusion with αPD-1 antibodies. This evidence concerns the gene PDCD1 and neoplasm.